207399-07-3
Chemical Structure
IR-780
- CAS No.: 207399-07-3
- Formula:C36H44ClIN2
- Molecular Weight:667.11
IUPAC Name: 2-((E)-2-((E)-2-chloro-3-(2-((Z)-3,3-dimethyl-1-propylindolin-2-ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-propyl-3H-indol-1-ium iodide
InChIKey: IRPKBYJYVJOQHQ-UHFFFAOYSA-M
SMILES: CCC[N+]1=C(/C=C/C2=C(Cl)/C(CCC2)=C/C=C3N(CCC)C4=C(C=CC=C4)C\3(C)C)C(C)(C)C5=C1C=CC=C5.[I-]
Biological Activity: IR-780 is a near-infrared fluorescent probe for in vivo imaging of tumor cells. IR-780 is transported into tumor cells via OATPs and ABCB10, with uptake dependent on glycolytic activity and plasma membrane potential. IR-780 preferentially accumulates in tumor cell mitochondria, including those of drug-resistant cancer cells, without chemical conjugation. IR-780 generates reactive oxygen species (ROS), induces hyperthermia and apoptosis, inhibits tumor growth and recurrence, and modulates HSP70 expression upon ultrasound or 808 nm laser exposure. IR-780 acts as a sonosensitizer, photodynamic and photothermal agent, and drug delivery carrier, with low acute imaging-dose toxicity and rapid vital organ clearance. IR-780 can be used for the research of cancer, such as breast cancer, lung cancer, and non-small cell lung cancer (NSCLC)[1][2][3][4][5][6][7][8][9][11].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
IR-780 | 99.93% | IR-780 is a near-infrared fluorescent probe for in vivo imaging of tumor cells. IR-780 is transported into tumor cells via OATPs and ABCB10, with uptake dependent on glycolytic activity and plasma membrane potential. IR-780 preferentially accumulates in tumor cell mitochondria, including those of drug-resistant cancer cells, without chemical conjugation. IR-780 generates reactive oxygen species (ROS), induces hyperthermia and apoptosis, inhibits tumor growth and recurrence, and modulates HSP70 expression upon ultrasound or 808 nm laser exposure. IR-780 acts as a sonosensitizer, photodynamic and photothermal agent, and drug delivery carrier, with low acute imaging-dose toxicity and rapid vital organ clearance. IR-780 can be used for the research of cancer, such as breast cancer, lung cancer, and non-small cell lung cancer (NSCLC). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zhang C, et al. A near-infrared fluorescent heptamethine indocyanine dye with preferential tumor accumulation for in vivo imaging. Biomaterials. 2010;31(25):6612-6617. [Content Brief]
- [2]. Chi Zhang, et al. Mitochondria-Targeting IR-780 Dye and Its Derivatives: Synthesis, Mechanisms of Action, and Theranostic Applications. Adv. Therap. 2018, 1800069.
- [3]. Li Y, et al. IR-780 Dye as a Sonosensitizer for Sonodynamic Therapy of Breast Tumor. Sci Rep. 2016;6:25968. Published 2016 May 13. [Content Brief]
- [4]. Wang Y, et al. Preferential accumulation of the near infrared heptamethine dye IR-780 in the mitochondria of drug-resistant lung cancer cells. Biomaterials. 2014;35(13):4116-4124. [Content Brief]
- [5]. Zhang E, et al. Mechanistic study of IR-780 dye as a potential tumor targeting and drug delivery agent. Biomaterials. 2014;35(2):771-778. [Content Brief]
- [6]. He W, et al. A versatile strategy to create an active tumor-targeted chemo-photothermal therapy nanoplatform: A case of an IR-780 derivative co-assembled with camptothecin prodrug. Acta Biomater. 2019;84:356-366. [Content Brief]
- [7]. Lu YJ, et al. Liposomal IR-780 as a Highly Stable Nanotheranostic Agent for Improved Photothermal/Photodynamic Therapy of Brain Tumors by Convection-Enhanced Delivery. Cancers (Basel). 2021;13(15):3690. Published 2021 Jul 22. [Content Brief]
- [8]. Yue C, et al. IR-780 dye loaded tumor targeting theranostic nanoparticles for NIR imaging and photothermal therapy. Biomaterials. 2013;34(28):6853-6861. [Content Brief]
- [9]. Baeten J, et al. Development of fluorescent materials for Diffuse Fluorescence Tomography standards and phantoms. Opt Express. 2007;15(14):8681-8694. [Content Brief]
